HK1046500A1 - 旋光纯(r)tofisopam用於治疗和预防焦虑症的用途及其组合物 - Google Patents

旋光纯(r)tofisopam用於治疗和预防焦虑症的用途及其组合物 Download PDF

Info

Publication number
HK1046500A1
HK1046500A1 HK02106802.3A HK02106802A HK1046500A1 HK 1046500 A1 HK1046500 A1 HK 1046500A1 HK 02106802 A HK02106802 A HK 02106802A HK 1046500 A1 HK1046500 A1 HK 1046500A1
Authority
HK
Hong Kong
Prior art keywords
tofisopam
treating
composition
anxiety disorders
optically pure
Prior art date
Application number
HK02106802.3A
Other languages
English (en)
Chinese (zh)
Inventor
W Landry Donald
F Klein Donald
Original Assignee
Vela Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc. filed Critical Vela Pharmaceuticals Inc.
Publication of HK1046500A1 publication Critical patent/HK1046500A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
HK02106802.3A 1998-10-27 1999-10-27 旋光纯(r)tofisopam用於治疗和预防焦虑症的用途及其组合物 HK1046500A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10580398P 1998-10-27 1998-10-27
US60105803 1998-10-27
PCT/US1999/025040 WO2000024400A1 (en) 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders and composition thereof

Publications (1)

Publication Number Publication Date
HK1046500A1 true HK1046500A1 (zh) 2003-01-17

Family

ID=22307874

Family Applications (2)

Application Number Title Priority Date Filing Date
HK02106802.3A HK1046500A1 (zh) 1998-10-27 1999-10-27 旋光纯(r)tofisopam用於治疗和预防焦虑症的用途及其组合物
HK02100988.2A HK1040908B (en) 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK02100988.2A HK1040908B (en) 1998-10-27 1999-10-27 Use of optically pure (r)-tofisopam for treating and preventing anxiety disorders

Country Status (16)

Country Link
EP (1) EP1124556B1 (https=)
JP (2) JP2003522112A (https=)
AT (1) ATE269705T1 (https=)
AU (1) AU1451900A (https=)
BR (1) BR9914899A (https=)
CA (1) CA2348281A1 (https=)
DE (1) DE69918322T2 (https=)
DK (1) DK1124556T3 (https=)
ES (1) ES2224751T3 (https=)
GB (1) GB2367748A (https=)
HK (2) HK1046500A1 (https=)
IL (2) IL142803A0 (https=)
NZ (1) NZ511744A (https=)
PT (1) PT1124556E (https=)
WO (1) WO2000024400A1 (https=)
ZA (1) ZA200103376B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649607B2 (en) 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
US20030232805A1 (en) * 2002-04-24 2003-12-18 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
CA2510275A1 (en) * 2002-12-03 2004-08-19 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof
US6864251B2 (en) * 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
US7022700B2 (en) 2002-12-03 2006-04-04 Vela Pharmaceuticals, Inc. Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
AU2003293405A1 (en) 2002-12-03 2004-06-23 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
CA2525273C (en) * 2003-05-16 2012-04-17 Vela Pharmaceuticals, Inc. Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
EP1689408A4 (en) * 2003-12-03 2010-03-03 Vela Acquisition Corp TREATMENT OF INFLAMMATORY DISORDERS OF EPITHELIUM USING LOW DOSE 2,3-BENZODIAZEPINES
FR2870539B1 (fr) * 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
US7541355B2 (en) 2005-05-23 2009-06-02 Vela Acquisition Corporation Conversion process for 2,3-benzodiazepine enantiomers
CN102836162A (zh) * 2012-04-10 2012-12-26 珠海亿邦制药股份有限公司 一种以托非索泮为活性成分的口服固体制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK118660B (da) * 1966-12-09 1970-09-21 Egyt Gyogyszervegyeszeti Gyar Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid.
ZA712798B (en) * 1970-11-06 1972-02-23 Egyt Gyogyszervegyeszeti Gyar New,pharmaceutically active 2,3-diazabicyclo(5.4.0)undecapentaene derivative and process for preparing same
HU178516B (en) * 1978-05-05 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing enanthiomeres of 1-bracket-3,4-dimethoxy-phenyl-bracket closed-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine and pharmacologically acceptable soles of the /-/-enanthiomere
HU209530B (en) * 1988-08-31 1994-07-28 Magnezitipari Muevek Rt Process for manufacturing of cromit-like, fire resistant materials

Also Published As

Publication number Publication date
JP2007211028A (ja) 2007-08-23
ES2224751T3 (es) 2005-03-01
GB2367748A8 (en) 2002-12-19
EP1124556B1 (en) 2004-06-23
EP1124556A1 (en) 2001-08-22
NZ511744A (en) 2004-04-30
HK1040908A1 (en) 2002-06-28
CA2348281A1 (en) 2000-05-04
DE69918322D1 (de) 2004-07-29
IL142803A0 (en) 2002-03-10
GB2367748A (en) 2002-04-17
PT1124556E (pt) 2004-10-29
ATE269705T1 (de) 2004-07-15
BR9914899A (pt) 2001-07-17
JP2003522112A (ja) 2003-07-22
ZA200103376B (en) 2003-09-09
HK1040908B (en) 2005-04-22
DE69918322T2 (de) 2005-09-15
IL142803A (en) 2006-10-05
AU1451900A (en) 2000-05-15
DK1124556T3 (da) 2004-10-11
WO2000024400A1 (en) 2000-05-04
GB0111739D0 (en) 2001-07-04

Similar Documents

Publication Publication Date Title
EP1143956A3 (en) Compositions and methods for the treatment of anorectal disorders
IL158775A0 (en) Use of an antioxidant for treating and or preventing surface ocular disorders
PL345275A1 (en) Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
EP1105113A4 (en) COMPILATION AND METHOD FOR TREATING PEYRONIE'S DISEASE AND OTHER DISEASES WITH THE APPLICATION OF SUB-DERMAL PLAQUES
AU4868599A (en) Composition for and method of treating neurological disorders
HK1046500A1 (zh) 旋光纯(r)tofisopam用於治疗和预防焦虑症的用途及其组合物
HUP0103842A3 (en) Method for the treatment of mania and bipolar disorder
BG106065A (en) Method for the treatment of neurological or neuropsychiatric disorders
CA2347863A1 (en) Treatment of disorders of the outer retina
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
AU2002362115A1 (en) Composition and methods for treatment of neurological disorders
AU2002363935A1 (en) Composition and method for the treatment of anorectal disorders
NZ324615A (en) Method for treating autism using olanzapine
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse
HUP0204209A3 (en) Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms
EP0888780A4 (en) COMPOSITION FOR TREATING CONTACT LENSES AND METHOD FOR USE THEREOF
AU2420101A (en) Method and composition for the treatment of pain
AU5446798A (en) Compositions and methods for the treatment of gastrointestinal disorders
AU5330599A (en) Methods and compositions for treating and preventing certain psychiatric and medical disorders using moclobemide
ZA9811840B (en) Methods and compositions for the treatment and prevention of tumors tumor-related disorders and cachexia
IL150202A0 (en) Method and composition for the treatment of pain
AU3275993A (en) Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
CA2387394A1 (en) Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
AU2215099A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
AUPM836794A0 (en) Improved method and composition for the treatment of ulcers